Cannabix Technologies Inc. BLOZF

Company Overview

Cannabix Technologies Inc. is a Canadian technology company focused on the development of non-invasive drug and alcohol detection technologies, with a primary emphasis on marijuana breath testing for law enforcement and workplace safety applications. The company operates within the broader public safety, diagnostic technology, and cannabis impairment detection industries. Its shares trade in Canada on the Canadian Securities Exchange under the symbol BLO and in the United States on the OTC market under the symbol BLOZF. Public filings and corporate disclosures indicate that the company’s core objective is to commercialize portable breathalyzer devices capable of detecting recent tetrahydrocannabinol (THC) exposure.

The company’s principal products and research initiatives include marijuana breathalyzer systems, alcohol breath screening technologies, and related roadside or workplace impairment detection solutions. Cannabix has positioned itself around the growing regulatory and public safety need for reliable impairment testing following cannabis legalization in multiple jurisdictions. The company evolved from an early-stage cannabis diagnostics developer into a specialized breath-testing technology company through internal research and partnerships with engineering and scientific collaborators. Available public disclosures indicate that its business model remains largely pre-commercial, with revenue generation historically limited relative to larger established diagnostics or law enforcement technology firms.

Business Operations

Cannabix Technologies conducts operations primarily through research, product development, intellectual property advancement, and prototype testing activities. Its principal business activities center on the development of marijuana breathalyzer technologies and alcohol screening devices, including contactless or rapid-screening systems intended for law enforcement agencies, employers, and public safety organizations. The company’s operational focus has included the refinement of THC collection and detection mechanisms, breath sample analysis systems, and sensor-based technologies intended to identify recent cannabis use rather than historical consumption measured through blood or urine testing.

The company operates primarily from Canada while pursuing commercial and research relationships in North America and internationally. Public disclosures reference collaborations with engineering consultants, laboratory specialists, and technology developers supporting prototype advancement and validation efforts. Cannabix has also reported work involving intellectual property protection through patent filings and technology licensing strategies. Data from public filings and corporate materials indicate that the company does not currently operate large-scale manufacturing infrastructure and instead relies on outsourced technical development and specialized partnerships for portions of product engineering and testing.

Strategic Position & Investments

Cannabix Technologies’ strategic direction has focused on achieving regulatory credibility and commercial adoption for cannabis impairment detection technologies. The company has invested substantially in research and development tied to THC breath detection, alcohol breath screening, and related sensor technologies. Publicly disclosed initiatives have included development of a contactless alcohol breathalyzer intended for workplace and public venue screening, as well as continued refinement of its THC breath collection systems. The company’s growth strategy appears centered on intellectual property development, prototype validation, and securing future commercialization opportunities in jurisdictions where cannabis legalization has increased demand for impairment testing solutions.

The company has also pursued patent-related activities and strategic collaborations intended to strengthen its competitive positioning in an emerging niche market. Available public records identify technology and engineering partnerships supporting product development, though disclosures do not indicate major transformative acquisitions comparable to larger public technology companies. Cannabix’s positioning is differentiated by its focus on detecting recent cannabis use through breath analysis rather than conventional bodily fluid testing. However, independent public reporting and filings indicate that widespread commercial deployment and regulatory approval remain ongoing objectives rather than fully realized milestones.

Geographic Footprint

Cannabix Technologies is headquartered in British Columbia, Canada, and its operations are concentrated primarily within Canada and the broader North American market. The company’s technology development efforts and investor communications have targeted law enforcement, workplace safety, and public health sectors in jurisdictions affected by cannabis legalization, including parts of the United States and Canada. Its shares trade publicly in both countries, contributing to cross-border investor visibility.

While the company does not maintain the extensive international operating infrastructure typical of multinational diagnostics firms, it has communicated intentions to address global demand for impairment testing technologies. Public disclosures and investor materials reference potential applicability in international transportation, law enforcement, and occupational safety environments. Data regarding significant overseas subsidiaries or material international operating revenue remains limited based on available public filings.

Leadership & Governance

Cannabix Technologies is governed by a board of directors and executive leadership team focused on technology commercialization, capital markets strategy, and product development within the impairment detection sector. The company’s leadership has consistently emphasized innovation in non-invasive testing technologies and the pursuit of scientifically validated solutions capable of addressing regulatory and public safety concerns related to cannabis impairment.

Key executives and leadership figures identified in public filings and corporate disclosures include:

• Rav Mlait – Chief Executive Officer
• Kal Malhi – Director
• Richard Goldstein – Chief Financial Officer
• Dr. Raj Attariwala – Scientific Advisor
• Dr. Bruce Goldberger – Scientific Advisor

Corporate governance information available through public filings indicates that leadership strategy has emphasized intellectual property development, scientific validation, and advancement toward commercial readiness. Data concerning broader executive succession planning or long-term governance restructuring is inconclusive based on available public sources.